Table 2.
Evaluation of binding potential for peptides derived from HPV and HCMV
| Peptide sequence | HLA allele | NetMHCpan evaluation | TransPHLA evaluation | |||
|---|---|---|---|---|---|---|
| %Rank | Bind level | Binding probability | Binding result | |||
| Original peptide (HPV) | ELQRREVYK | HLA-A*11:01 | 1.864 | Weak binder | 0.003 | Non-binding |
| Mutated peptide (HPV) | ALQRREVYK | HLA-A*11:01 | 0.408 | Strong binder | 0.995 | Binding |
| Original peptide (HCMV) | KEVNSQLSL | HLA-B*15:10 | 1.002 | Weak binder | 0.000 | Non-binding |
| Mutated peptide (HCMV) | FEVNSQLSL | HLA-B*15:10 | 0.269 | Strong binder | 0.993 | Binding |
%Rank: rank of the predicted binding score compared to a set of random natural peptides introduced by NetMHCpan. Peptides will be identified as weak binder if the %Rank is above the threshold of the strong binders (by default, 0.5%) but below the threshold of the weak binders (by default, 2%). Binding probability: the binding probability predicted by TransPHLA. Peptides will be identified as non-binding to the HLA allele if the binding probability is below the default threshold 0.5.